Doctor

Glaucoma is one of the leading causes of visual impairment and irreversible blindness. Globally, more than 60 million people suffer from it and this number could rise to over......

Recorded a particularly high rate of new cases of infection among contact lens wearers

The use of contaminated contact lenses has led to a significant increase in cases of Acanthamoeba keratitis in the South East of England, with rates almost tripling in 2010-2011 compared to the period......

On the occasion of World Diabetes Day 2018, which, as every year, falls on 14 November, more than 6,000 pharmacies throughout Italy have joined the national campaign of......

The control of medicines, in general, is based on precise rules relating to Good Manufacturing Practice (GMP) of medicines in order to ensure the......

1. Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Uveitis Affecting the Posterior Segment: 12-Month Results. Jaffe GJ, Foster S, Pavesio C, Paggiarino D, Riedel GE.......

Only 25% of diabetic patients undergo an annual examination. A joint effort of diabetologists and ophthalmologists is needed for increased early diagnosis

In Italy today, diabetic retinopathy (DR) affects over one million people; a growing trend due to both the late diagnosis of type 2 diabetes (when complications, between......

Chlamydia trachomatis infection is stabilised but not eradicated by repeated antibiotic treatment

Rates of ocular chlamydia among children living in hyper-endemic areas of Africa can be stabilised with mass, annual or biannual azithromycin administrations, however based on......

Patient enrolment in the Phase III clinical study (ODAK 043/SI) aimed at developing a safe and effective drug for the treatment of Acanthamoeba keratitis.

  The phase III clinical trial of the ODAK (Orphan Drug for Acanthamoeba Keratitis) Project (ODAK 043/SI) passes the 50% milestone (65 out of 130) after one year (https://www.oculistaitaliano.it/articoli/progetto-odak-parte-italia-lo-studio-clinico-fase-iii/) by......